Physician profile
Theodore A Bash
NPI 1215987235
$18,731.54
in general payments reported to CMS, 2019-2025
38 companies · $13.76 in 2025
The $13.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $1,058 · 2021: $1,296 · 2022: $1,238 · 2023: $1,243 · 2024: $576 · 2025: $13.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745 · Education: $88.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.97 |
| Education | $88.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11,710.00 | 2019-2020 | |
| Lilly USA, LLC | $999.58 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Novo Nordisk INC | $920.77 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $730.65 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.88 | 2020-2024 | Stiolto Respimat, Jardiance |
| Abbvie INC. | $460.37 | 2019-2023 | Vraylar |
| Novartis Pharmaceuticals Corporation | $456.28 | 2019-2024 | |
| Pfizer INC. | $357.22 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $341.51 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $270.61 | 2019-2023 | Xarelto |
| Amgen INC. | $244.02 | 2019-2024 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $243.03 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $217.08 | 2019-2023 | Rexulti |
| Mylan Specialty L.P. | $185.09 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $154.39 | 2019-2025 | Eohilia |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Bash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.